PSA screening--current controversy.

There is perhaps no more contentious issue in Urology in 1998 than how and if PSA screening for prostate cancer should be applied. The issue must be discussed in the absence of completed randomized clinical trials, and arguments must be supported by extrapolated clinical data in the medical literature. Because of data which can be interpreted often in two different manners, groups and organizations including patient's groups, governmental agencies, medical organizations, and managed care providers often find themselves at odds with each other with regards to recommendations regarding PSA screening.

Intermittent azoospermia associated with epididymal sarcoidosis.

Objective: To report an unusual case of intermittent azoospermia associated with epididymal sarcoidosis.

Design: Retrospective case analysis.

Setting: Wilford Hall Medical Center.

Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer.

Purpose: Many investigators use prostate rebiopsy as an indicator of treatment efficacy and tumor response of localized prostate cancer for therapies in which the gland remains in situ. Because of the inherent sampling error of needle directed biopsies, however, some men will have a false-negative rebiopsy even if they have had no therapy or if the therapeutic intervention was unsuccessful in eradicating the malignancy. We evaluate the risk of a false-negative biopsy and the clinical factors that influence this risk.

The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.

Purpose: Parenteral testosterone supplementation is a common treatment for erectile dysfunction in hypogonadal men. Despite its frequent use, the effect of testosterone on prostate specific antigen (PSA) in these patients has not been documented previously. In this study we determined the effect of parenteral testosterone replacement on PSA and PSA velocity in a group of men being treated for erectile dysfunction.